You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR SIMPONI ARIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SIMPONI ARIA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01212653 ↗ Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) Completed Chinese University of Hong Kong Phase 4 2010-10-01 1. To determine the effect of Golimumab treatment on the number and function of Endothelial Progenitor Cells (EPCs) in Ankylosing Spondylitis(AS) patients as a possible mechanism for the effect of this treatment on endothelial function. 2. To ascertain the effect of Golimumab treatment on , carotid intima-media thickness, vascular stiffness in Ankylosing Spondylitis(AS) patients as measured by pulse wave velocity (PWV) and Augmentation index (AIx). 3. To assess the clinical efficacy of Golimumab in Chinese Ankylosing Spondylitis(AS) patients according to ASAS response criteria at month 3, 6 and 12. 4. To perform cost-effectiveness and cost-utility analyses of the Golimumab in Ankylosing Spondylitis(AS) patients, using clinic-base data.
NCT01258777 ↗ A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects Completed Centocor, Inc. Phase 1 2010-10-01 The purpose of this study is to evaluate the pharmacokinetics of golimumab in Japanese and Caucasian Males.
NCT01288157 ↗ A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects Completed Centocor, Inc. Phase 1 2010-09-01 The purpose of this study is to evaluate the pharmacokinetics of golimumab in Chinese male participants.
NCT01313858 ↗ A Study to Investigate the Use of Golimumab (SimponiĀ®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) Completed Merck Sharp & Dohme Corp. 2010-04-01 This is a study to assess the use of golimumab (SimponiĀ®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (SimponiĀ®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SIMPONI ARIA

Condition Name

Condition Name for SIMPONI ARIA
Intervention Trials
Psoriatic Arthritis 8
Rheumatoid Arthritis 6
Arthritis, Psoriatic 3
Ulcerative Colitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SIMPONI ARIA
Intervention Trials
Arthritis 14
Arthritis, Psoriatic 11
Arthritis, Rheumatoid 7
Colitis, Ulcerative 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SIMPONI ARIA

Trials by Country

Trials by Country for SIMPONI ARIA
Location Trials
United States 24
Germany 4
Canada 4
China 4
Netherlands 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SIMPONI ARIA
Location Trials
Pennsylvania 3
Washington 2
Arizona 2
Virginia 2
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SIMPONI ARIA

Clinical Trial Phase

Clinical Trial Phase for SIMPONI ARIA
Clinical Trial Phase Trials
Phase 4 13
Phase 3 6
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SIMPONI ARIA
Clinical Trial Phase Trials
Completed 13
Not yet recruiting 5
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SIMPONI ARIA

Sponsor Name

Sponsor Name for SIMPONI ARIA
Sponsor Trials
Janssen Scientific Affairs, LLC 3
Janssen Research & Development, LLC 3
Merck Sharp & Dohme Corp. 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SIMPONI ARIA
Sponsor Trials
Other 21
Industry 17
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.